SCHEMBL4268243

SCHEMBL4268243

O=C(CON1C(=O)c2ccccc2C1=O)Nc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.60
ALDH1A1 P00352 3/20 0.60
CYP2C9 P11712 2/20 0.60
MEN1 O00255 2/20 0.60
CYP1A2 P05177 1/20 0.60
HPGD P15428 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MAPT P10636 2/20 0.49
ALOX12 P18054 1/20 0.49
MAPK1 P28482 1/20 0.49
HTT P42858 1/20 0.49
NPC1 O15118 1/20 0.48
LMNA P02545 1/20 0.48
CYP2D6 P10635 1/20 0.48
RAB9A P51151 1/20 0.48
KLK7 P49862 1/20 0.48
GAA P10253 1/20 0.47
KDM4E B2RXH2 2/20 0.47
NOTUM Q6P988 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4267439 0.81 ALDH1A1 (0.59) KMT2AALDH1A1CYP2C9MEN1CYP1A2
SCHEMBL221092 0.80 ALDH1A1 (0.72) KMT2AALDH1A1CYP2C9MEN1CYP1A2
SCHEMBL11385742 0.78 ALDH1A1 (0.56) KMT2AALDH1A1CYP2C9MEN1CYP1A2
SCHEMBL11388585 0.77 ALDH1A1 (0.55) KMT2AALDH1A1CYP2C9MEN1CYP1A2
SCHEMBL13479820 0.76 KMT2A (0.53) KMT2AALDH1A1CYP2C9MEN1CYP1A2
SCHEMBL6693868 0.76 KMT2A (1.00) KMT2AALDH1A1CYP2C9MEN1HPGD
SCHEMBL28658136 0.76 ALDH1A1 (1.00) KMT2AALDH1A1CYP2C9MEN1CYP1A2
SCHEMBL1562501 0.76 ALDH1A1 (0.61) KMT2AALDH1A1CYP2C9MEN1CYP1A2
SCHEMBL8610167 0.75 ALDH1A1 (0.65) KMT2AALDH1A1CYP2C9MEN1CYP1A2
SCHEMBL4279628 0.75 ALDH1A1 (0.65) KMT2AALDH1A1CYP2C9MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-5246969-A None JP disclosed
US-7608627-B2 I kappa B kinase inhibition; diabetes; (7-Chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol; N-Benzyl-7-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-27 US disclosed
US-20080064715-A1 6-Azaindole Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-03-13 US disclosed
JP-H05246969-A AMINOXYFATTY ACID DERIVATIVE AND ENZYME INHIBITOR SANKYO CO LTD 1993-09-24 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064715-A1 6-Azaindole Compound RELA, NFKBIA, GPR119 KMT2A 1114/4885ALDH1A1 3508/4885CYP2C9 1914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.